VIFOR PHARMA GROUP INCREASES EQUITY INVESTMENT IN CHEMOCENTRYX - Seite 2

Heide Hauer
Head of Corporate Communications
Tel.: [phone]
E-mail: [e-mail] Investor Relations
Julien Vignot
Head of Investor Relations
Tel.: [phone]
E-mail: [e-mail]

  ChemoCentryx Contacts   Media
Stephanie Tomei 
Tel.: [phone]
E-mail: [e-mail] Investors
Steve Klass at Burns McClellan
Tel.: [phone]
E-mail: [e-mail]

 

Avacopan is currently in late-stage clinical development for the treatment of rare diseases, including rare inflammatory renal diseases. Avacopan is a first in class, oral, highly selective inhibitor of the complement C5a receptor (C5aR) which is central to the underlying pathophysiology of Anti-neutrophil cytoplasmic antibody associated vasculitis (AAV), a group of rare, serious autoimmune diseases which lead to significant morbidity and mortality. In a randomized, double-blind, placebo controlled Phase II clinical study in AAV patients, the CLEAR trial, avacopan demonstrated a favourable risk/benefit profile and therapeutic efficacy to control active vasculitis rapidly. By blocking the terminal effector complement protein C5a, avacopan can selectively inhibit the AAV inflammatory cycle involving the complement system and neutrophils while preserving the function of the C5b-9 membrane attack complex which is important in the immune response to encapsulated bacterial infection.

CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease. ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Vifor Pharma Group is a global pharmaceuticals company. It aims to become global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for specialty pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, visit www.viforpharma.com.